The Company


Glycologic Limited develops carbohydrate-based products for the food and drink, clinical nutrition and pharmaceutical sectors. These products include active nutritional ingredients (ANIs), active pharmaceutical ingredients (APIs), delivery systems, nutritional systems and diagnostics. The Company collaborates with a broad range of companies to market these technologies and to develop products on a one to one basis.

Based in the UK, the Company has an extensive range of national and international partners with customers located throughout the world. Nutrition, over the counter (OTC) and prescription only medicine (POM or Rx) ingredients used in many healthcare products have been developed by the Company and act to optimise health and protect against disease. 

Licensed Technologies

Different technologies targeted at different healthcare issues and include:

  • Liver disease
  • Diabetes
  • Glycogen storage disease
  • Toxic carbohydrate derivative detection
  • Sports nutrition
  • Cardio-vascular disease
  • Gut health (various)
  • Hypo- and hyperglycaemia management
  • Gastric reflux
  • Nutrient and drug delivery
  • Inborn errors of metabolism (various)

Current Trials

Clinical trials active at this time include:

  • Carbohydrate digestion control
  • Clinical nutrition products (e.g. blood glucose control, low-protein, high-protein, gut-health and ketogenic)
  • Sleep enhancement technology
  • Digestive health technology
  • Dysphagia management
  • Novel approaches to GORD (GERD) therapy

Partnering opportunities

The Company is always receptive to partnering and collaborations. Areas of particular interest at this time are:

  • Oral delivery systems
  • Hypo- and hyperglycaemia management
  • Epilepsy management and therapy through ketogenic products
  • Low protein diets
  • High protein diets
  • Gut health
  • Sport nutrition
  • Skin health and healing
  • Sleep therapy
  • GORD therapy
  • Dysphagia
  • Weight maintenance

Email us at for more details.